Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
<h4>Objective</h4>This study aims to assess the cost-effectiveness of adebrelimab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) from the Chinese medical perspective.<h4>Methods</h4>We have designed a partitione...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0325171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218928376119296 |
|---|---|
| author | Zhiwei Zheng Huide Zhu Ling Fang |
| author_facet | Zhiwei Zheng Huide Zhu Ling Fang |
| author_sort | Zhiwei Zheng |
| collection | DOAJ |
| description | <h4>Objective</h4>This study aims to assess the cost-effectiveness of adebrelimab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) from the Chinese medical perspective.<h4>Methods</h4>We have designed a partitioned survival model. The model integrates clinical information pertaining to overall survival, progression-free survival, adverse events and cost data. Our primary measure of outcome in this model is quality-adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). The model adopted a willingness to pay (WTP) threshold of $40,343.68 per QALY. To account for uncertainty in the model parameters, we conducted sensitivity analyses.<h4>Results</h4>The total expenditure for the adebrelimab group was $79,549.34, compared to $6,436.80 for the chemotherapy group. The adebrelimab cohort achieved an incremental gain of 1.25 QALY, resulting in an additional cost of $73,112.54. Consequently, the ICER for the adebrelimab group was determined to be $58,490.03 per QALY, surpassing the WTP threshold of $40,343.68 in China. The sensitivity analyses demonstrated the robustness of the findings across various scenarios.<h4>Conclusion</h4>This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen. |
| format | Article |
| id | doaj-art-c8b84405ccec4a8586d6917e004546ab |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c8b84405ccec4a8586d6917e004546ab2025-08-20T02:07:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01206e032517110.1371/journal.pone.0325171Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.Zhiwei ZhengHuide ZhuLing Fang<h4>Objective</h4>This study aims to assess the cost-effectiveness of adebrelimab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) from the Chinese medical perspective.<h4>Methods</h4>We have designed a partitioned survival model. The model integrates clinical information pertaining to overall survival, progression-free survival, adverse events and cost data. Our primary measure of outcome in this model is quality-adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). The model adopted a willingness to pay (WTP) threshold of $40,343.68 per QALY. To account for uncertainty in the model parameters, we conducted sensitivity analyses.<h4>Results</h4>The total expenditure for the adebrelimab group was $79,549.34, compared to $6,436.80 for the chemotherapy group. The adebrelimab cohort achieved an incremental gain of 1.25 QALY, resulting in an additional cost of $73,112.54. Consequently, the ICER for the adebrelimab group was determined to be $58,490.03 per QALY, surpassing the WTP threshold of $40,343.68 in China. The sensitivity analyses demonstrated the robustness of the findings across various scenarios.<h4>Conclusion</h4>This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen.https://doi.org/10.1371/journal.pone.0325171 |
| spellingShingle | Zhiwei Zheng Huide Zhu Ling Fang Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. PLoS ONE |
| title | Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. |
| title_full | Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. |
| title_fullStr | Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. |
| title_full_unstemmed | Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. |
| title_short | Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. |
| title_sort | cost effectiveness analysis of adebrelimab in combination with chemotherapy for first line treatment of extensive stage small cell lung cancer |
| url | https://doi.org/10.1371/journal.pone.0325171 |
| work_keys_str_mv | AT zhiweizheng costeffectivenessanalysisofadebrelimabincombinationwithchemotherapyforfirstlinetreatmentofextensivestagesmallcelllungcancer AT huidezhu costeffectivenessanalysisofadebrelimabincombinationwithchemotherapyforfirstlinetreatmentofextensivestagesmallcelllungcancer AT lingfang costeffectivenessanalysisofadebrelimabincombinationwithchemotherapyforfirstlinetreatmentofextensivestagesmallcelllungcancer |